FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]
FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
We would like to use the opportunity to share with you the link to a new book which has finally been released (fresh from the electronic press!) and to which Anke-Peggy Holtorf has contributed two chapters (“Market Access in Germany” and, together with Nigel Cook, “The Role of Patients in Market Access“). Kockaya G, […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]
FiercePharma, 22. Apr. 2015 Japan’s health regulators are in the midst of deciding how to conduct cost-effective assessments for drugs and medical devices with under the Central Social Insurance Medical Council, better known as Chuikyo. The Government of Prime Minister Shinzo Abe adopted a plan last year that stipulates the trial rollout of cost-effective assessments […]
There is a lot of talk in industry, among the public, or among payers about VALUE related to health services or products. But do they mean the same, when they talk about it. Read a recent (March 2015) assay by Ed Schoonveld in ‘PharmExec.com’ : http://www.pharmexec.com/can-payers-and-drug-industry-agree-real-value?
Fierce Pharma, February 19, 2015 | By Eric Palmer Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a […]
Fierce Pharma, February 20, 2015 | By Emily Wasserman Bayer has won an approval from England’s National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The drugmaker offered a discount to get the approval and then NICE granted it for some, but not all, […]